ARGENX SE news, videos and press releases - Page 3
For more news please use our advanced search feature.
ARGENX SE - More news...
ARGENX SE - More news...
- argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
- argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
- argenx to Present at Upcoming Investor Conferences
- argenx Reports First Quarter 2023 Financial Results and Provides Business Update
- argenx announces results of Annual General Meeting of Shareholders
- argenx to Present at BofA Securities 2023 Health Care Conference
- argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023
- argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting
- argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
- argenx Announces Annual General Meeting of Shareholders on May 2, 2023
- argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
- argenx Announces Planned Transition of Chief Operating Officer
- argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
- argenx Appoints Steve Krognes to Board of Directors
- argenx to Present at Upcoming Investor Conferences
- argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
- argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
- argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
- argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
- argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
- argenx Appoints Ana Cespedes to Board of Directors
- argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
- argenx Enters Into Agreement To Acquire Priority Review Voucher
- argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
- argenx to Present at Upcoming Investor Conferences
- argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
- argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
- argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings
- argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis
- argenx Appoints Camilla Sylvest to Board of Directors
